Pharmacodynamic assessment of a novel P2Y 12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention

Thrombosis Research

Volumn 129, Issue 5, 2012, Pages 623-628

  Yokoi, Hiroyoshi ^a   Kimura, Takeshi ^b   Isshiki, Takaaki ^c   Ogawa, Hisao ^d   Ikeda, Yasuo ^e  

^a KOKURA MEMORIAL HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c TEIKYO UNIVERSITY HOSPITAL   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e WASEDA UNIVERSITY   (Japan)

Author keywords

Antiplatelet effect; Clopidogrel; Coronary artery disease; Percutaneous coronary intervention; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG POTENCY; DRUG WITHDRAWAL; FEMALE; HUMAN; JAPANESE; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STENT THROMBOSIS; SUBCUTANEOUS HEMORRHAGE; THROMBOCYTE AGGREGATION INHIBITION; UNSPECIFIED SIDE EFFECT; URINARY OCCULT BLOOD; URINARY TRACT HEMORRHAGE;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TICLOPIDINE; YOUNG ADULT;

EID: 84860427595     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.11.023     Document Type: Article

References (15)

1. C. Combescure, P. Fontana, N. Mallouk, P. Berdague, C. Labruyere, and I. Barazer Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis J Thromb Haemost 8 2010 923 933
2. J.A. Jakubowski, K.J. Winters, H. Naganuma, and L. Wallentin Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile Cardiovasc Drug Rev 25 2007 357 374
3. J.T. Brandt, C.D. Payne, S.D. Wiviott, G. Weerakkody, N.A. Farid, and D.S. Small A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 2007 66.e9 66.e16
4. T. Jernberg, C.D. Payne, K.J. Winters, C. Darstein, J.T. Brandt, and J.A. Jakubowski Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin treated patients with stable coronary artery disease Eur Heart J 27 2006 1166 1173
5. S.D. Wiviott, D. Trenk, A.L. Frelinger, M. O'Donoghue, F.J. Neumann, and A.D. Michelson Prasugrel compared with high loading- and maintenance dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial Circulation 116 2007 2923 2932
6. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
7. D.S. Small, P. Kothare, E. Yuen, D.R. Lachno, Y.G. Li, and K.J. Winters The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects Eur J Clin Pharmacol 66 2010 127 135
8. D.S. Small, C.D. Payne, P. Kothare, E. Yuen, F. Natanegara, and M. Teng Loh Pharmacodynamics and Pharmacokinetics of Single Doses of Prasugrel 30 mg and Clopidogrel 300 mg in Healthy Chinese and White Volunteers: An Open-Label Trial Clin Ther 32 2 2010 365 379
9. K. Hoshino, H. Horiuchi, T. Tada, J. Tazaki, E. Nishi, and M. Kawato Clopidogrel Resistance in Japanese Patients Scheduled for Percutaneous Coronary Intervention Circ J 73 2009 336 342
10. Y.G. Li, L. Ni, J.T. Brandt, D.S. Small1, C.D. Payne, and C.S. Ernest II Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects* Platelets 20 5 2009 316 327
11. K. Nakamura, F. Goto, W.A. Ray, C.B. McAllister, E. Jacqz, and G.R. Wilkinson Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations Clin Pharmacol Ther 38 4 1985 402 408
12. M. Jurima, T. Inaba, D. Kadar, and W. Kalow Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians Br J Clin Pharmacol 19 4 1985 483 487
13. H. Muller, F. Besta, C. Schulz, S. Massberg, A. Schönig, and M. Gawaz Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement Thromb Haemost 89 2003 783 787
14. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Bienart, and I. Goldenberg Clopidogrel resistance is associated with risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
15. L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, and O. Wittenberg Adjusted Clopidogrel Loading Doses According to Vasodilator- Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance J Am Coll Cardiol 51 2008 1404 1411